Sudan Loganathan
Stock Analyst at Stephens & Co.
(2.27)
# 2,557
Out of 4,883 analysts
38
Total ratings
53.33%
Success rate
-4.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $43.62 | +37.55% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $12.76 | +96.00% | 3 | Jun 23, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Equal-Weight | $150 → $135 | $128.35 | +5.18% | 3 | Jun 3, 2025 | |
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.37 | +1,256.85% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.50 | +252.94% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $21.19 | +55.73% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $2.67 | +199.63% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $21.13 | +136.63% | 2 | Feb 14, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.03 | +113.52% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $11.70 | +164.96% | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $44.44 | +35.01% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.36 | +269.00% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.51 | +164.90% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.63 | +620.84% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.08 | +1,103.70% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.85 | +1,029.94% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.05 | +878.00% | 1 | May 14, 2024 |
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $43.62
Upside: +37.55%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $12.76
Upside: +96.00%
Blueprint Medicines
Jun 3, 2025
Downgrades: Equal-Weight
Price Target: $150 → $135
Current: $128.35
Upside: +5.18%
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.37
Upside: +1,256.85%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.50
Upside: +252.94%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $21.19
Upside: +55.73%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $2.67
Upside: +199.63%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $21.13
Upside: +136.63%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.03
Upside: +113.52%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $11.70
Upside: +164.96%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $44.44
Upside: +35.01%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.36
Upside: +269.00%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.51
Upside: +164.90%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.63
Upside: +620.84%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.08
Upside: +1,103.70%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.85
Upside: +1,029.94%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.05
Upside: +878.00%